Literature DB >> 23573840

Role of comorbid conditions in asthma hospitalizations in the south of France.

C Aubas1, A Bourdin, P Aubas, A S Gamez, L Halimi, I Vachier, N Malafaye, P Chanez, N Molinari.   

Abstract

BACKGROUND: Reasons for asthma hospitalizations are dynamic and complex. Comorbid conditions are important contributors to most chronic diseases today. We aim to characterize and describe risk factors associated with hospitalizations due to asthma in the Languedoc-Roussillon region (France) in 2009.
METHODS: Programme de Médicalisation des Systèmes d'Information (PMSI) data records from 2009 were sorted using selected International Classification of Diseases (ICD10) codes eliciting three groups of asthma hospitalizations according to acute severity. All available data including demographics, comorbid conditions, past hospitalizations either related or unrelated to asthma, seasonality and distance to medical facilities were used to compare the subjects within the three groups.
RESULTS: One thousand two hundred and eighty-nine hospitalizations due to asthma exacerbation were found, concerning 1122 patients. We observed significant differences within the groups, using univariate analysis, concerning duration of hospitalizations (mean ± SD, 4.9 ± 5.9 days vs 6.4 ± 6.8 vs 15.8 ± 16.8, P < 0.001), deaths (percentage, 0.03% vs 1.50% vs 9.20%, P < 0.001) and numbers of comorbid conditions (0.80 ± 0.95 vs 0.75 ± 0.97 vs 1.74 ± 1.36, P < 0.001). Recurrent admissions for asthma during the period 2006-2008 were significantly more frequent in the more severe group (1.93 ± 3.91 vs 2.56 ± 4.47 vs 2.81 ± 3.97, P = 0.006). In the multivariate model, age and number of comorbid conditions were independently associated with severe hospitalizations and deaths.
CONCLUSIONS: Asthma hospitalizations can be appropriately assessed using PMSI coding databases. In this study, age and the presence of comorbid conditions are the major risk factors for asthma hospitalizations and deaths.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23573840     DOI: 10.1111/all.12137

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

1.  Inequities in ambulatory care and the relationship between socioeconomic status and respiratory hospitalizations: a population-based study of a canadian city.

Authors:  Aaron J Trachtenberg; Natalia Dik; Dan Chateau; Alan Katz
Journal:  Ann Fam Med       Date:  2014 Sep-Oct       Impact factor: 5.166

Review 2.  Challenges in the Management of Asthma in the Elderly.

Authors:  Woo Jung Song; Sang Heon Cho
Journal:  Allergy Asthma Immunol Res       Date:  2015-04-10       Impact factor: 5.764

3.  Long-term future risk of severe exacerbations: Distinct 5-year trajectories of problematic asthma.

Authors:  A C A Yii; J H Y Tan; T S Lapperre; A K W Chan; S Y Low; T H Ong; K L Tan; S H Chotirmall; P J Sterk; M S Koh
Journal:  Allergy       Date:  2017-04-25       Impact factor: 13.146

4.  The pharmacotherapy preferred by doctors in treatment of patients diagnosed with asthma or chronic obstructive pulmonary disease or allergic rhinitis and concomitant diseases: an epidemiological analysis.

Authors:  Marcin Nowak; Grzegorz Brożek; Zbigniew Doniec; Magdalena Olszanecka-Glinianowicz
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

5.  Age- and sex-specific prevalence of chronic comorbidity in adult patients with asthma: A real-life study.

Authors:  Mathijs Veenendaal; Janine A M Westerik; Lisette van den Bemt; Janwillem W H Kocks; Erik W Bischoff; Tjard R Schermer
Journal:  NPJ Prim Care Respir Med       Date:  2019-04-29       Impact factor: 2.871

6.  The impact of comorbidities on productivity loss in asthma patients.

Authors:  Solmaz Ehteshami-Afshar; J Mark FitzGerald; Christopher Carlsten; Hamid Tavakoli; Roxanne Rousseau; Wan Cheng Tan; J Douglass Rolf; Mohsen Sadatsafavi
Journal:  Respir Res       Date:  2016-08-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.